Medicare Enrolled
Dr. Rahul Kale, MD
Pulmonary Disease · San Juan Capistrano, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Kale from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kale?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Kale
Dr. Rahul Kale is a pulmonary disease specialist in San Juan Capistrano, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Kale performed 2,594 Medicare services across 732 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kale received a total of $4,122 from 42 pharmaceutical and/or device companies across 206 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kale is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 15% volume in CA
$4,122 industry payments
Medicare Practice Summary
Medicare Utilization ↗2,594
Medicare services
Top 15% in CA for pulmonary disease
732
Unique beneficiaries
$116
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~137 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Nursing facility visit, high complexity A follow-up visit by a healthcare provider at a nursing facility for an established patient. The visit involves a high level of medical decision making and takes at least 45 minutes. |
778 | $129 | $336 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
541 | $102 | $242 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
468 | $177 | $646 |
| Prolonged nursing facility care, each 15 minutes This code covers additional time spent by a physician or qualified professional in a nursing facility beyond the standard duration of the primary evaluation and management service. |
164 | $26 | $75 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
163 | $148 | $373 |
| Additional 30 minutes of critical care This code represents an additional 30 minutes of critical care services provided beyond the initial critical care time period. |
104 | $89 | $284 |
| Prolonged office E/M service, first 15 minutes This code is used for additional time spent by a physician beyond the maximum required time of a primary office or outpatient evaluation and management service. It is billed in 15-minute increments based on total time spent on the date of the primary service. |
73 | $27 | $78 |
| Prolonged inpatient or observation care, each additional 15 minutes This code is used for prolonged hospital inpatient or observation care services that extend beyond the total time required for the primary evaluation and management service. It covers each additional 15-minute increment of time spent by the provider. |
56 | $26 | $75 |
| Overnight continuous oxygen level test This test measures oxygen levels in the blood continuously overnight using a device attached to the ear or finger. |
48 | $24 | $37 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
43 | $147 | $439 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
28 | $50 | $142 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
27 | $34 | $146 |
| Initial nursing facility care, high complexity An initial visit by a healthcare provider to a patient in a nursing facility involving a high level of medical decision making, lasting at least 45 minutes. |
24 | $147 | $405 |
| Advance care planning consultation, first 30 min A session focused on discussing and documenting future healthcare preferences and goals. This service covers the initial 30 minutes of the planning discussion. |
19 | $70 | $195 |
| New patient office visit, complex (60-74 min) | 18 | $185 | $500 |
| Lung volume test using gas dilution or washout A test that measures the amount of air in your lungs by using a gas dilution or washout method. |
16 | $40 | $110 |
| Lung volume test using sensors A test that measures the amount of air in the lungs using sensors. |
12 | $46 | $140 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
12 | $81 | $269 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$4,122
Total received (2018-2024)
Avg $687/year across 6 years
Top 30% in CA for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
42
Companies
206
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,105 (99.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$17 (0.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,138
2023
$841
2022
$201
2020
$180
2019
$778
2018
$984
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
GlaxoSmithKline, LLC.
$310
AstraZeneca Pharmaceuticals LP
$103
Actelion Pharmaceuticals US, Inc.
$85
Axsome Therapeutics, Inc.
$81
Regeneron Healthcare Solutions, Inc.
$67
Takeda Pharmaceuticals U.S.A., Inc.
$65
Boehringer Ingelheim Pharmaceuticals, Inc.
$63
GENZYME CORPORATION
$59
Vifor Pharma, Inc.
$49
Insmed, Inc.
$49
Grifols USA, LLC
$32
Mylan Specialty L.P.
$28
Lilly USA, LLC
$27
Avadel CNS Pharmaceuticals, LLC
$26
JAZZ PHARMACEUTICALS INC.
$23
United Therapeutics Corporation
$22
Novo Nordisk Inc
$17
Electromed, Inc.
$17
Pulmonx Corporation
$15
Top 3 companies account for 43.8% of 2024 payments
All-time payments by company (2018-2024) ›
GlaxoSmithKline, LLC.
$589
Actelion Pharmaceuticals US, Inc.
$416
Boehringer Ingelheim Pharmaceuticals, Inc.
$337
Genentech USA, Inc.
$330
Grifols USA, LLC
$312
Takeda Pharmaceuticals U.S.A., Inc.
$254
AstraZeneca Pharmaceuticals LP
$185
Mylan Specialty L.P.
$173
GENZYME CORPORATION
$123
Insmed, Inc.
$115
Regeneron Healthcare Solutions, Inc.
$102
Shire North American Group Inc
$88
Lilly USA, LLC
$83
Axsome Therapeutics, Inc.
$81
Philips Electronics North America Corporation
$77
ABBVIE INC.
$71
Baxter Healthcare
$64
Jazz Pharmaceuticals Inc.
$62
Electromed, Inc.
$52
Fisher & Paykel Healthcare Inc
$51
Vifor Pharma, Inc.
$49
United Therapeutics Corporation
$48
JAZZ PHARMACEUTICALS INC.
$40
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$38
SANOFI-AVENTIS U.S. LLC
$37
Janssen Pharmaceuticals, Inc
$33
Harmony Biosciences LLC
$33
SANOFI PASTEUR INC.
$32
Circassia Pharmaceuticals Inc
$29
Mallinckrodt Hospital Products Inc.
$27
Avadel CNS Pharmaceuticals, LLC
$26
Exact Sciences Corporation
$23
Almatica Pharma LLC
$18
Novo Nordisk Inc
$17
Sanofi Pasteur Inc.
$17
Advanced Respiratory, Inc
$16
Pulmonx Corporation
$15
Medtronic MiniMed, Inc.
$14
Bayer HealthCare Pharmaceuticals Inc.
$13
Endogastric Solutions, Inc
$13
Abbott Laboratories
$12
Merck Sharp & Dohme Corporation
$11
Top 3 companies account for 32.5% of all-time payments
Associated products mentioned in payments ›
(9356) DS2 A cell FG · (9360) DS2A A cell FG · ACTHAR · AREXVY · Adempas · Arikayce · BEXSERO · BREO · CHARTIS CATHETER · CINRYZE · CUVITRU · Cologuard Collection Kit · DUPIXENT · ESOPHYX · Esbriet · FASENRA · FISHER & PAYKEL HEALTHCARE · FLUZONE QUADRIVALENT · FLUZONE QUADRIVALENT NORTHERN HEMISPHERE · GLASSIA · HYQVIA · Hillrom - Life 2000 Ventilation System · JANUVIA · LOREEV XR · LUMRYZ · MOUNJARO · NO PRODUCT DISCUSSED · NUCALA · OFEV · OPSUMIT · OPSUMIT MACITENTAN · Obstructive Sleep Apnea Device or Hospital Respiratory Equipment · Prolastin-C · Prolastin-C Liquid · S&RC Und · SHINGRIX · SMARTVEST · SOLIQUA · SPIRIVA · STIOLTO RESPIMAT · SUNOSI · Sunosi · Supera peripheral stent system · TEZSPIRE · TRELEGY ELLIPTA · TRULICITY · TUDORZA PRESSAIR · TYVASO · The Vest System Model 105 Home Care · Trintellix · UBRELVY · UPTRAVI · VYVANSE · Wakix · Wegovy · XARELTO · XIFAXAN · XYWAV · Xolair · Xyrem · YUPELRI · Yupelri · Zemaira · iPro2 · inCourage
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Pulmonary diseases within 10 mi
69
Per 100K population
2.2
County median income
$113,702
Nearest hospital
ALISO RIDGE BEHAVIORAL HEALTH, LLC
6.8 mi
6.8 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Kale is a mixed practice specialist, with above-average Medicare volume (top 15% in CA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Kale experienced with nursing facility visit, high complexity?
Based on Medicare claims data, Dr. Kale performed 778 nursing facility visit, high complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kale receive payments from pharmaceutical companies?
Yes. Dr. Kale received a total of $4,122 from 42 companies across 206 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kale's costs compare to other pulmonary diseases in San Juan Capistrano?
Dr. Kale's average Medicare payment per service is $116. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kale) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in San Juan Capistrano
Browse pulmonary diseases in San Juan Capistrano ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in CA
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in CA
Which CA pulmonary diseases receive the most from drug and device companies.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
Actelion Pharmaceuticals US, Inc. Payments to Doctors
See all physicians who received payments from Actelion Pharmaceuticals US, Inc.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology